Phase II study of doxorubicin and mitomycin in non-small cell bronchogenic carcinoma.
Thirty patients with advanced measurable non-small cell bronchogenic carcinoma were treated with a combination of doxorubicin (50 mg/m2 every 3 weeks) and mitomycin (20 mg/m2 every 6 weeks). One complete and three partial responses were observed. This response rate is similar to that reported for either drug used alone.
D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008937:Mitomycins / Q000627:therapeutic use*
D008937:Mitomycins; D004317:Doxorubicin